Innovation in bone healing and tissue repair
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.

Kuros has developed a pipeline of clinical and preclinical programmes at various stages of development and generated significant data in a number of indications and applications. The most advanced programmes are targeting commercially attractive opportunities in certain segments of the tissue repair and regeneration space, notably sealants and orthobiologics. In addition to many years of substantial preclinical work, Kuros Biosurgery has now enrolled over 600 patients in multi-national clinical trials, generating promising safety and efficacy in a number of indications.

Latest News
23 Jun 16
First Trading Day of New Kuros Share after Reverse Split
Schlieren (Zurich), Switzerland, June 23, 2016 – Kuros Biosciences Ltd (“Kuros”) today......READ MORE
16 Jun 16
Kuros Bioscience’s Shareholders Approve All Resolutions
Kuros Biosciences Ltd (“Kuros”) today announced that its shareholders approved......READ MORE
Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 (0)44 200 56 00   Fax: +41 (0)44 200 56 01   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board
  • Careers

    Products

    1. Pipeline
    2. Sealants
      Surgical sealants
      KUR-023
    3. Orthobiologics
      Fracture repair
      KUR-111
      KUR-113
      Spinal fusion
      KUR-113

    Technologies

    1. Overview
    2. Fibrin-based
    3. Synthetic-based
    4. Immune modulation
    5. Publications

    Partnerships

    1. Collaborations
    2. Business development

    Investors

    1. Share price
    2. Regulatory filings
    3. Reports & presentations
    4. Calendar
    5. Corporate governance
    6. Stay informed

    News & Events

    1. Press releases
    2. Conferences & Events

    Contact

    1. Location
  • Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.

    Kuros has developed a pipeline of clinical and preclinical programmes at various stages of development and generated significant data in a number of indications and applications. The most advanced programmes are targeting commercially attractive opportunities in certain segments of the tissue repair and regeneration space, notably sealants and orthobiologics. In addition to many years of substantial preclinical work, Kuros Biosurgery has now enrolled over 600 patients in multi-national clinical trials, generating promising safety and efficacy in a number of indications.

    Latest News
    23 Jun 16
    First Trading Day of New Kuros Share after Reverse Split
    Schlieren (Zurich), Switzerland, June 23, 2016 – Kuros Biosciences Ltd (“Kuros”) today......READ MORE
    16 Jun 16
    Kuros Bioscience’s Shareholders Approve All Resolutions
    Kuros Biosciences Ltd (“Kuros”) today announced that its shareholders approved......READ MORE